Improving Inhaled Product Testing: Methods for Obtaining Better In vitro-In vivo Relationships - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Improving Inhaled Product Testing: Methods for Obtaining Better In vitro-In vivo Relationships
Even in an industry in which all product development is complicated by the intricacies of human biology, orally inhaled products (OIP) stand out as singularly demanding.


Pharmaceutical Technology
Volume 37, Issue 2

References

1. Y. Zhang, K. Gilbertson, and W.H. Finlay, J. Aerosol Medicine 20 (3) 227-235 (2007).

2. M. Hamilton and D. Prime, "A Rapid In-vitro Dry Powder Inhaler Device Equivalence Screening Study Using the Hydraulic Lung," poster presentation at Drug Delivery to the Lungs (DDL) 22 (Edinburgh, Scotland, 2011).

3. B. Olsson, et al., Proceedings of Respiratory Drug Delivery 2008 Conference (Phoenix, AZ, 2008), Vol 1, pp. 197-205.

4. B. Olsson, E. Berg, and M. Svensson, Proceedings of Respiratory Drug Delivery 2010 Conference (Orlando, FL, 2010), pp. 225–234.

5. M. Svensson and E. Berg, Proceedings of Respiratory Drug Delivery 2008 Conference (Phoenix, AZ, 2008), pp. 391-394.

6. Y. Zhang, T. L. Chia, and W. Finlay, Aerosol Sci. and Tech. 40 (5), 361-372 (2006).

7. M. Copley, J. Mitchell, and D. Solomon, Inhalation 5 (4) 12-16 (2011).

8. A. Watkins, T. Gerrish, and N. Childerhouse, Proceedings of Respiratory Drug Delivery 2012 Conference (Phoenix, AZ, 2012), pp. 877-882.

9. B. Grgic, W.H. Finlay, and A.F.Heenan, J. Aerosol Sci. 35 (1) 21-32 (2004).

10. Y. Zhou, J. Sun, and Y.S. Cheng, J. Aerosol Med. and Pulmonary Drug Deliv. 24 (6) 277-284 (2011).

11. M. Rahmatalla, et al., J. Aerosol Med. 15 (4) 379–385 (2002).

12. W. Finlay, Proceedings of Respiratory Drug Delivery 2012 Conference (Phoenix, AZ, 2012), pp. 325-336.

13. N.C. Miller, M.J. Maniaci, S. Dwivedi, and G.W. Ward, Proceedings of Respiratory Drug Delivery Conference (Orlando, FL, 2000), pp. 191-196.

14. W. Finlay and M.G. Gehmlich, Intl. J. of Pharmaceutics 210 (1-2) 83-95 (2000).

15. Eur. Ph., 7.3 (Supplement) Chapter 2.9.44, "Preparations for Nebulisation: Characterisation" (EDQM, Strasbourg, France, 2012), 3803-3805.

16. USP 34-NF 29 First Supplement, General Chapter <1601>, "Products for Nebulization–Characterization Tests" (US Pharmacopeial Convention, Rockville, MD, 2011), pp. 4729-4732.

17. D.K. Nadarassan, K.H.Assi, and H. Chrystyn, Eur. J. Pharm. Sci. 39 (5)348-354 (2010).

18. D.Harris, Pharm. Tech. Eur. 19 (9) 29-35 (2007).

19. P. Burnell, et al., J. Aerosol Sci. 29 (8), 1011-1025 (1998).

20. M. Copley, J. Mitchell, E. McAulay and D. Russell-Graham, Inhalation 4 (1) 7-11 (2010).

21. J. Mitchell, et al., J. Aerosol Med. and Pulmonary Drug Deliv. 25 (4) 188-197 (2012).

22. G.Keegan and D.A.Lewis, Proceedings of Respiratory Drug Delivery 2012 Conference (Phoenix, AZ, 2012), pp. 465-468.

23. G.Keegan and D.A.Lewis, Proceedings of Respiratory Drug Delivery 2012 Conference (Phoenix, AZ, 2012), pp. 469-472.

24. S. Newman and H-K. Chan, J. Aerosol Medicine 21 (1) 1-8 (2008).

Mark Copley is sales director at Copley Scientific, Colwick Quays Business Park, Private Road No. 2, Colwick, Nottingham, NG4 2JY, UK, Tel: +44 0 115 961 6229, http://www.copleyscientific.com/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here